Moderna's mRNA-based flu vaccine showed stronger immune response in trials, paving the way for approval. The company plans to resubmit a combination flu and Covid jab for approval, aiming for both shots to be approved next year. The vaccine simplifies vaccination, reducing costs and improving patient uptake.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing